News and Announcements

AstraZeneca's Datroway and Enhertu candidates receive EU approval

By Iain Gilbert

Date: Monday 29 Jun 2026

(Sharecast News) - Drugmaker AstraZeneca said on Monday that its breast cancer therapy Datroway has been recommended for approval in the EU as a first‑line monotherapy for adults with unresectable or metastatic triple‑negative breast cancer who are not eligible for PD‑1/PD‑L1 inhibitor treatment.
AstraZeneca said the positive opinion from the European...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page